



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: CELG

Last Trade:	103.15
Trade Time:	4:00 PM ET Nov 20, 2017
Change:	-0.95 (0.913%)
Day Range	102.41 - 105.46
52-Week Range	94.55 - 147.17
Volume	6,183,743

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID<sup>®</sup>, VIDAZA<sup>®</sup>, THALOMID<sup>®</sup>, POMALYST<sup>®</sup>/IMNOVID<sup>®</sup>, ABRAXANE<sup>®</sup>, OTEZLA<sup>®</sup>, ISTODAX<sup>®</sup> and IDHIFA<sup>®</sup>. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Nov 16, 2017  
[Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma](#)

Nov 1, 2017  
[Celgene Prices \\$3 Billion of Senior Unsecured Notes](#)

Oct 31, 2017  
[Celgene Announces Offering of Senior Unsecured Notes](#)

Oct 28, 2017  
[Efficacy and Safety Results from Second Phase III Trial \(RADIANCE™ Part B\) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting](#)

Oct 27, 2017  
[Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod \(SUNBEAM™\) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting](#)

## Upcoming Events [\[ View all \]](#)

Nov 30, 2017 11:00 AM ET  
[Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)

## Events [\[ View all \]](#)

## Financials [\[ View all \]](#)

Feb 10, 2017  
[Annual Report \(10-K\)](#)

Apr 27, 2017  
[Proxy Statement \(DEF 14A\)](#)

Oct 26, 2017  
[Quarterly Report \(10-Q\)](#)

Jul 27, 2017  
[Quarterly Report \(10-Q\)](#)

Apr 27, 2017  
[Quarterly Report \(10-Q\)](#)

